<p><strong>德克薩斯州達拉斯，2025 年 12 月 19 日（全球新聞通訊）--</strong> Mangoceuticals, Inc.（納斯達克代碼：MGRX）（“公司”）是一家專注於通過安全的遠程醫療平台開發、營銷和銷售各種健康和保健產品的公司，旗下品牌包括 MangoRx 和 PeachesRx。今天，公司宣佈完成其之前宣佈的註冊直接發行和與機構投資者的同時私募。公司在註冊直接發行中發行了普通股和預融資認股權證。在同時的私募中，公司還向同一投資者發行了投資者認股權證。兩項交易的總毛收入約為 250 萬美元。交易於 2025 年 12 月 19 日完成。交易價格符合納斯達克規則的市場價格。</p>
<p>交易包括銷售 1,930,502 個普通單位（或預融資單位），每個單位包括（i）一（1）股普通股或一（1）個預融資認股權證，以及（ii）一個（1）個 PIPE 普通認股權證，每個認股權證可購買一（1）股普通股，行使價格為 1.4245 美元。每個普通單位的發行價格為 1.295 美元（或每個預融資單位為 1.29499 美元，等於發行中每個普通單位的發行價格減去每個預融資認股權證的行使價格 0.00001 美元）。預融資認股權證可立即行使，並可在完全行使之前的任何時間行使。對於在發行中銷售的每個預融資單位，發行中的普通單位數量將按一對一的比例減少。</p>
<p>公司總毛收入約為 250 萬美元。交易於 2025 年 12 月 19 日完成。公司預計將利用發行的淨收益以及現有現金用於一般企業用途和營運資金。</p>
<p><strong>Aegis Capital Corp.擔任此次發行的獨家配售代理。Lucosky Brookman LLP 擔任公司的法律顧問。Kaufman &amp; Canoles, P.C.擔任 Aegis Capital Corp.的法律顧問。</strong></p>
<p>此次註冊直接發行是根據之前向美國證券交易委員會（SEC）提交併於 2025 年 6 月 24 日獲得 SEC 批准的有效貨架註冊聲明（編號 333-288039）進行的。最終的招股説明書補充及相關招股説明書將提交給 SEC，並將在 SEC 網站 www.sec.gov 上提供。最終招股説明書補充及相關招股説明書的電子副本可在可用時通過聯繫 Aegis Capital Corp.，注意：承銷部，1345 Avenue of the Americas，27 樓，紐約，NY 10105，電子郵件 syndicate@aegiscap.com，或電話 +1（212）813-1010 獲取。</p>
<p>私募中證券的發行和銷售是在不涉及公開發行的交易中進行的，並且未根據《1933 年證券法》（修訂版）（“證券法”）或適用的州證券法進行註冊。因此，除非根據有效的註冊聲明或適用的證券法註冊要求的豁免，否則這些證券不得在美國重新發行或轉售。證券僅向合格投資者提供。根據與投資者的註冊權協議，公司已同意向 SEC 提交一份或多份註冊聲明，涵蓋普通股的轉售以及在行使預融資認股權證和認股權證時可發行的股份。</p>
<p>本新聞稿不構成出售要約或購買要約的徵求，也不應在任何州或司法管轄區進行這些證券的銷售，除非在該州或司法管轄區的證券法下注冊或合格之前，這種要約、徵求或銷售是非法的。</p>
<p><strong>關於 Mangoceuticals, Inc.</strong></p>
<p>MangoRx 專注於通過安全的遠程醫療平台開發各種男性健康和保健產品及服務。迄今為止，公司已將男性健康遠程醫療服務和產品確定為一個增長領域，特別是與勃起功能障礙（ED）、毛髮生長、激素替代療法和體重管理相關的領域。感興趣的消費者可以使用 MangoRx 的遠程醫療平台獲得順暢的體驗。處方請求將由醫生審核，如果獲得批准，將通過 MangoRx 的合作藥房進行履行，並直接送到患者家門口。要了解更多關於 MangoRx 的使命和其他產品的信息，請訪問 www.MangoRx.com。</p>
<p><strong>前瞻性聲明</strong></p>
<p>上述材料可能包含根據 1933 年證券法第 27A 條和 1934 年證券交易法第 21E 條（均已修訂）所定義的 “前瞻性聲明”。前瞻性聲明包括所有不單純涉及歷史或當前事實的聲明，包括但不限於關於公司的產品開發和商業前景的聲明，並且可以通過使用 “可能”、“將”、“期望”、“項目”、“估計”、“預期”、“計劃”、“相信”、“潛在”、“應該”、“繼續” 或這些詞的否定形式或其他可比詞彙來識別。前瞻性聲明並不保證未來的行動或表現。這些前瞻性聲明基於公司當前可獲得的信息及其當前計劃或預期，並受到可能顯著影響當前計劃的多種風險和不確定性的制約。如果這些風險或不確定性中的一個或多個實現，或基礎假設被證明不正確，實際結果可能與預期、相信、估計、期望、意圖或計劃的結果有顯著差異。儘管公司相信前瞻性聲明中反映的期望是合理的，但公司無法保證未來的結果、表現或成就。除非適用法律（包括美國的證券法）要求，否則公司不打算更新任何前瞻性聲明以使這些聲明與實際結果相符。</p>
<p>投資者關係</p>
<p>Mangoceuticals 投資者關係</p>
<p>電子郵件：investors@mangorx.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd05URTVOaU0zTXpNd056azFJelV3TURFeE5qRXdOUT09?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd05URTVOaU0zTXpNd056azFJelV3TURFeE5qRXdOUT09"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YWJkNDNmYzItZTljYy00MmFmLTg4ZDItNzljMmZjMWQwZTM1LTUwMDExNjEwNS0yMDI1LTEyLTE5LWVu/tiny/Mangoceuticals-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YWJkNDNmYzItZTljYy00MmFmLTg4ZDItNzljMmZjMWQwZTM1LTUwMDExNjEwNS0yMDI1LTEyLTE5LWVu/tiny/Mangoceuticals-Inc-.png"/></p>

MGRX

<p>Mangoceuticals, Inc.（納斯達克代碼：MGRX）宣佈完成一項 250 萬美元的註冊直接發行和與機構投資者的同時私募。該公司發行了普通股和預先融資的認股權證，交易於 2025 年 12 月 19 日完成。所得款項將用於一般企業用途和營運資金。Aegis Capital Corp. 擔任獨家配售代理。此次發行是在向美國證券交易委員會（SEC）提交的有效的貨架註冊聲明下進行的</p>

<p><strong>DALLAS, TX, Dec. 19, 2025 (GLOBE NEWSWIRE) --</strong> Mangoceuticals, Inc. (NASDAQ: MGRX) (the “Company”), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, today announced the closing of its previously announced registered direct offering and concurrent private placement with institutional investors. The Company issued shares of Common Stock and pre-funded warrants in a registered direct offering. In a concurrent private placement, the Company also issued to the same investors investor warrants. Aggregate gross proceeds to the Company from both transactions were approximately $2.5 million. The transactions closed on December 19, 2025. The transactions were priced at the market under Nasdaq rules.</p>
<div class="lb-trans"><p><strong>德克薩斯州達拉斯，2025 年 12 月 19 日（全球新聞通訊）--</strong> Mangoceuticals, Inc.（納斯達克代碼：MGRX）（“公司”）是一家專注於通過安全的遠程醫療平台開發、營銷和銷售各種健康和保健產品的公司，旗下品牌包括 MangoRx 和 PeachesRx。今天，公司宣佈完成其之前宣佈的註冊直接發行和與機構投資者的同時私募。公司在註冊直接發行中發行了普通股和預融資認股權證。在同時的私募中，公司還向同一投資者發行了投資者認股權證。兩項交易的總毛收入約為 250 萬美元。交易於 2025 年 12 月 19 日完成。交易價格符合納斯達克規則的市場價格。</p>
</div><p>The transactions consisted of the sale of 1,930,502 Common Units (or Pre-Funded Units), each consisting of (i) one (1) share of Common Stock or one (1) Pre-Funded Warrant and (ii) one (1) PIPE Common Warrant to purchase one (1) share of Common Stock per warrant at an exercise price of $1.4245. The offering price per Common Unit is $1.295 (or $1.29499 for each Pre-Funded Unit, which is equal to the offering price per Common Unit sold in the offering minus an exercise price of $0.00001 per Pre-Funded Warrant). The Pre-Funded Warrants are immediately exercisable and may be exercised at any time until exercised in full. For each Pre-Funded Unit sold in the offering, the number of Common Units in the offering will be decreased on a one-for-one basis.</p>
<div class="lb-trans"><p>交易包括銷售 1,930,502 個普通單位（或預融資單位），每個單位包括（i）一（1）股普通股或一（1）個預融資認股權證，以及（ii）一個（1）個 PIPE 普通認股權證，每個認股權證可購買一（1）股普通股，行使價格為 1.4245 美元。每個普通單位的發行價格為 1.295 美元（或每個預融資單位為 1.29499 美元，等於發行中每個普通單位的發行價格減去每個預融資認股權證的行使價格 0.00001 美元）。預融資認股權證可立即行使，並可在完全行使之前的任何時間行使。對於在發行中銷售的每個預融資單位，發行中的普通單位數量將按一對一的比例減少。</p>
</div><p>Aggregate gross proceeds to the Company were approximately $2.5 million. The transaction closed on December 19, 2025. The Company expects to use the net proceeds from the offerings, together with its existing cash, for general corporate purposes and working capital.</p>
<div class="lb-trans"><p>公司總毛收入約為 250 萬美元。交易於 2025 年 12 月 19 日完成。公司預計將利用發行的淨收益以及現有現金用於一般企業用途和營運資金。</p>
</div><p><strong>Aegis Capital Corp. acted as exclusive placement agent for the offerings. Lucosky Brookman LLP acted as counsel to the Company. Kaufman &amp; Canoles, P.C. acted as counsel to Aegis Capital Corp.</strong></p>
<div class="lb-trans"><p><strong>Aegis Capital Corp.擔任此次發行的獨家配售代理。Lucosky Brookman LLP 擔任公司的法律顧問。Kaufman &amp; Canoles, P.C.擔任 Aegis Capital Corp.的法律顧問。</strong></p>
</div><p>The registered direct offering was being made pursuant to an effective shelf registration statement on Form S-3 (No. 333-288039) previously filed with the U.S. Securities and Exchange Commission (SEC) and declared effective by the SEC on June 24, 2025. A final prospectus supplement and accompanying prospectus describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC’s website located at www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying prospectus may be obtained, when available, by contacting Aegis Capital Corp., Attention: Syndicate Department, 1345 Avenue of the Americas, 27th floor, New York, NY 10105, by email at syndicate@aegiscap.com, or by telephone at +1 (212) 813-1010.</p>
<div class="lb-trans"><p>此次註冊直接發行是根據之前向美國證券交易委員會（SEC）提交併於 2025 年 6 月 24 日獲得 SEC 批准的有效貨架註冊聲明（編號 333-288039）進行的。最終的招股説明書補充及相關招股説明書將提交給 SEC，並將在 SEC 網站 www.sec.gov 上提供。最終招股説明書補充及相關招股説明書的電子副本可在可用時通過聯繫 Aegis Capital Corp.，注意：承銷部，1345 Avenue of the Americas，27 樓，紐約，NY 10105，電子郵件 syndicate@aegiscap.com，或電話 +1（212）813-1010 獲取。</p>
</div><p>The offer and sale of the securities in the private placement were made in a transaction not involving a public offering and have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or applicable state securities laws. Accordingly, the securities may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. The securities were offered only to accredited investors. Pursuant to a registration rights agreement with the investors, the Company has agreed to file one or more registration statements with the SEC covering the resale of the Common Stock and the Shares issuable upon exercise of the pre-funded warrants and warrants.</p>
<div class="lb-trans"><p>私募中證券的發行和銷售是在不涉及公開發行的交易中進行的，並且未根據《1933 年證券法》（修訂版）（“證券法”）或適用的州證券法進行註冊。因此，除非根據有效的註冊聲明或適用的證券法註冊要求的豁免，否則這些證券不得在美國重新發行或轉售。證券僅向合格投資者提供。根據與投資者的註冊權協議，公司已同意向 SEC 提交一份或多份註冊聲明，涵蓋普通股的轉售以及在行使預融資認股權證和認股權證時可發行的股份。</p>
</div><p>This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</p>
<div class="lb-trans"><p>本新聞稿不構成出售要約或購買要約的徵求，也不應在任何州或司法管轄區進行這些證券的銷售，除非在該州或司法管轄區的證券法下注冊或合格之前，這種要約、徵求或銷售是非法的。</p>
</div><p><strong>About Mangoceuticals, Inc.</strong></p>
<div class="lb-trans"><p><strong>關於 Mangoceuticals, Inc.</strong></p>
</div><p>MangoRx is focused on developing a variety of men’s health and wellness products and services via a secure telemedicine platform. To date, the Company has identified men’s wellness telemedicine services and products as a growing sector and especially related to the area of erectile dysfunction (ED), hair growth, hormone replacement therapies, and weight management. Interested consumers can use MangoRx’s telemedicine platform for a smooth experience. Prescription requests will be reviewed by a physician and, if approved, fulfilled and discreetly shipped through MangoRx’s partner compounding pharmacy and right to the patient’s doorstep. To learn more about MangoRx’s mission and other products, please visit www.MangoRx.com.</p>
<div class="lb-trans"><p>MangoRx 專注於通過安全的遠程醫療平台開發各種男性健康和保健產品及服務。迄今為止，公司已將男性健康遠程醫療服務和產品確定為一個增長領域，特別是與勃起功能障礙（ED）、毛髮生長、激素替代療法和體重管理相關的領域。感興趣的消費者可以使用 MangoRx 的遠程醫療平台獲得順暢的體驗。處方請求將由醫生審核，如果獲得批准，將通過 MangoRx 的合作藥房進行履行，並直接送到患者家門口。要了解更多關於 MangoRx 的使命和其他產品的信息，請訪問 www.MangoRx.com。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性聲明</strong></p>
</div><p>The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding the Company’s product development and business prospects, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of risks and uncertainties that could significantly affect current plans. Should one or more of these risks or uncertainties materialize, or the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, performance, or achievements. Except as required by applicable law, including the security laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.</p>
<div class="lb-trans"><p>上述材料可能包含根據 1933 年證券法第 27A 條和 1934 年證券交易法第 21E 條（均已修訂）所定義的 “前瞻性聲明”。前瞻性聲明包括所有不單純涉及歷史或當前事實的聲明，包括但不限於關於公司的產品開發和商業前景的聲明，並且可以通過使用 “可能”、“將”、“期望”、“項目”、“估計”、“預期”、“計劃”、“相信”、“潛在”、“應該”、“繼續” 或這些詞的否定形式或其他可比詞彙來識別。前瞻性聲明並不保證未來的行動或表現。這些前瞻性聲明基於公司當前可獲得的信息及其當前計劃或預期，並受到可能顯著影響當前計劃的多種風險和不確定性的制約。如果這些風險或不確定性中的一個或多個實現，或基礎假設被證明不正確，實際結果可能與預期、相信、估計、期望、意圖或計劃的結果有顯著差異。儘管公司相信前瞻性聲明中反映的期望是合理的，但公司無法保證未來的結果、表現或成就。除非適用法律（包括美國的證券法）要求，否則公司不打算更新任何前瞻性聲明以使這些聲明與實際結果相符。</p>
</div><p>FOR INVESTOR RELATIONS</p>
<div class="lb-trans"><p>投資者關係</p>
</div><p>Mangoceuticals Investor Relations</p>
<div class="lb-trans"><p>Mangoceuticals 投資者關係</p>
</div><p>Email: investors@mangorx.com</p>
<div class="lb-trans"><p>電子郵件：investors@mangorx.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd05URTVOaU0zTXpNd056azFJelV3TURFeE5qRXdOUT09" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYwNTE5NiM3MzMwNzk1IzUwMDExNjEwNQ=="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YWJkNDNmYzItZTljYy00MmFmLTg4ZDItNzljMmZjMWQwZTM1LTUwMDExNjEwNS0yMDI1LTEyLTE5LWVu/tiny/Mangoceuticals-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/YWJkNDNmYzItZTljYy00MmFmLTg4ZDItNzljMmZjMWQwZTM1LTUwMDExNjEwNS0yMDI1LTEyLTE5LWVu/tiny/Mangoceuticals-Inc-.png"/></p>

Mangoceuticals, Inc. 宣佈完成 250 萬美元的註冊直接發行和私募配售 | MGRX 股票新聞